triple negative breast cancer

[Cell Death & Disease] Integrated affinity purification combined with mass spectrometry and TCGA analysis identified a cell cycle-related E3 ubiquitin ligase, checkpoint with forkhead and ring finger domains (CHFR), as a key negative regulator of zinc finger E-box-binding homeobox 1 (ZEB1) in TNBC.

[HUTCHMED] HUTCHMED initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s tislelizumab in patients with advanced triple negative breast cancer or advanced endometrial cancer in the US. This trial is to explore the potential for the addition of a highly selective vascular endothelial growth factor receptor inhibitor, fruquintinib, to anti-programmed death-1 antibody tislelizumab in inducing activity to immune checkpoint inhibitors.

[Genentech] Genentech announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® in combination with chemotherapy for the treatment of adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1, as determined by a US FDA-approved test.

[Molecular Therapy] The authors identified a circRNA termed circ-EIF6, which predicted a poorer prognosis and correlated with clinicopathological characteristics in a cohort of TNBC patients. Functionally, they showed that circ-EIF6 promoted the proliferation and metastasis of TNBC cells in vitro and in vivo.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers found that except for SP1, the other tethering partners of ERβ (Fos, Jun, Fra1) were down-regulated in TNBC, meaning that the tumor-suppressive functions of ERβ were severely compromised.

[Cell Death Discovery] The authors investigated the function and underlying mechanisms of novel circPDCD11 in TNBC aerobic glycolysis and revealed that circPDCD11 expression was significantly upregulated in TNBC tissues and cells.